Tytuł: Profilaktyka zakażeń pneumokokowych – od okresu niemowlęcego po późną starość / Prophylaxis for pneumococcal infectious – from infancy until late elderly age

Słowa kluczowe: POKRYCIE SZCZEPIONKOWE SKONIUGOWANE SZCZEPIONKI PNEUMOKOKOWE INWAZYJNA CHOROBA PNEUMOKOKOWA ODPOWIEDŹ IMMUNOLOGICZNA
Keywords: IMMUNE RESPONSE THE VACCINES COVERED CONJUGATES PNEUMOCOCCAL VACCINES INVASIVE PNEUMOCOCCAL DISEASES

Autorzy:
Ewa Bernatowska - Klinika Gastroenterologii, Hepatologii i Immunologii IP-CZD

48.7% and 74.4% of all IPD cases up to 2 years of age (www.koroun.edu.pl). However, for the protection against pneumococcal pneumonia,
sinusitis and recurrent acute otitis media (AOM) mucosal immunity is required. PCV13 vaccine provides protection of the mucous membranes,
in particular by reducing pneumococcal carriage, thereby inhibiting the spread of infection to the entire population. This results in a decrease
in the incidence of invasive and non-invasive pneumococcal infections in all age groups – vaccination produces herd immunity. On the other
hand, introduction of universal vaccination with the PCV10 vaccine, which has a limited ability to reduce the carriage, is the cause of increased
infections with antibiotic-resistant 19A serotype in the population of patients over 2 years old, observed in countries where PCV10 is administered.
The Paediatric Group of Experts on the Protective Vaccinations Programme by the Minister for Health recommends that the PCV13 vaccine be included
in the mandatory vaccinations programme in children up to 2 years of age, considering the widest range of protection that it provides as well as the
health benefits for the whole unvaccinated population.